Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
Providers may consider this off-label based on individual clinical judgment, but it requires careful evaluation, informed consent, and ongoing monitoring
Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease
.png)
doi: 10.2174/1568026619666190709101449 120 WoldEAGarciaEJWildCTMiszkielJMSotoCAChenJ
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
Between mid-2024 and early 2025, monthly US searches for "GLP-1 patches" surged from near zero to over 57,000, driven entirely by consumer interest in cheaper, easier alternatives to GLP-1 injections
Glp1r -expressing cells were abundant at every level from the cervical to the coccygeal end of the spinal cord, predominantly in the gray matter, along with a few cells in the white matter (Fig
